Premium
Bortezomib: an effective agent in extramedullary disease in multiple myeloma
Author(s) -
Laura Rosiñol,
Cibeira Ma Teresa,
Uriburu Carla,
Yantorno Sebastián,
Salamero Olga,
Bladé Joan,
Montserrat Emili
Publication year - 2006
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.0902-4441.2005.t01-1-ejh2462.x
Subject(s) - bortezomib , thalidomide , multiple myeloma , medicine , proteasome inhibitor , refractory (planetary science) , disease , oncology , cancer research , biology , astrobiology
Bortezomib is a potent and selective proteasome inhibitor recently introduced in the treatment of multiple myeloma (MM). This drug produces significant responses in about one‐third of patients with relapsed/refractory disease. We first recognized the lack of efficacy of thalidomide in soft‐tissue plasmacytomas. There is little information on the effect of bortezomib on extramedullary myeloma. Four of 23 patients treated with bortezomib at our institution had extramedullary involvement at the time of relapse. In three of these patients large soft‐tissue plasmacytomas disappeared. This indicates that bortezomib may be useful in clinical situations of extramedullary disease in which other agents, such as thalidomide, may not be effective.